We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?
Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?
Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.
Aachen, Germany and Leuven, Belgium, April 09, 2018 – Grünenthal, the Katholieke Universiteit Leuven’s Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need.
Aachen, Germany, February 01, 2018 – Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP) designation by the U.S. Food and Drug Administration (FDA) for VIVO. VIVO is a surgical sealant proposed for being an adjunct to standard closure techniques in gastrointestinal procedures to reduce intestinal leakage. VIVO is a candidate from Grünenthal’s innovative development-pipeline of surgical sealants. Flix®, the first product from this portfolio, already obtained CE-Certification in Europe.